VRTX · Healthcare

VERTEX PHARMACEUTICALS INC / MA

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-09-23

• Product / Drug Pipeline ProgressImportance 51 · Surprise 74
  Vertex reported positive Phase IIb AMPLIFIED results for inaxaplin in patients with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and type 2 diabetes. Inaxaplin produced a 42.7%…

News · 2026-09-22

• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Vertex reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease (AMKD), including a 42.7% reduction in urine albumin-to-creatinine ratio among patients with modest proteinuria and a…

News · 2026-09-15

• JOURNAVX Demand and AccessImportance 29 · Surprise 30
  Vertex partnered with Olympic skier Lindsey Vonn to promote JOURNAVX, its non-opioid pain treatment. Vonn is advocating for the drug after suffering a severe leg injury at the 2026 Winter Games and experiencing…

News · 2026-09-14

• Litigation and Legal RiskImportance 47 · Surprise 60
  The U.S. Court of Appeals for the D.C. Circuit affirmed that Vertex’s Fertility Support Program would violate the federal Anti-Kickback Statute. The program offered up to $70,000 in fertility services to patients using…

News · 2026-09-10

• Product / Drug Pipeline ProgressImportance 31 · Surprise 42
  Vertex is broadening beyond cystic fibrosis into renal disease, pain management, hematology, and rare endocrinology to build a diversified commercial portfolio across five therapeutic areas. Near-term catalysts include…

News · 2026-09-08

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for approximately $10 billion. The transaction expands Vertex’s portfolio beyond cystic fibrosis into rare-disease therapies. Third-party reporting…

News · 2026-09-01

• Crinetics Acquisition FinancingImportance 75 · Surprise 60
  Vertex completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, for approximately $10.0 billion in equity value. The transaction adds PALSONIFY and atumelnant and establishes rare endocrine diseases…

News · 2026-08-26

• KALYDECO Generic CompetitionImportance 40 · Surprise 42
  A U.S. federal judge ruled that Lupin Ltd.'s proposed generic versions of Vertex's cystic-fibrosis drug KALYDECO do not infringe four Vertex patents. The dispute focused on the interpretation of the patented ivacaftor…

News · 2026-08-25

• Litigation and Legal RiskImportance 40 · Surprise 42
  A federal judge ruled that Lupin’s proposed generic versions of Vertex’s cystic fibrosis drug Kalydeco do not infringe four Vertex patents. The court dismissed Vertex’s infringement lawsuit after finding that its…
• KALYDECO Generic CompetitionImportance 40 · Surprise 42
  A federal judge ruled that Lupin’s proposed generic versions of Vertex’s cystic fibrosis drug KALYDECO do not infringe four Vertex patents. The court found Vertex’s patent claims covering an “about 80%”…
• Licensing / Collaboration DealsImportance 31 · Surprise 42
  AbCellera Biologics reported a new collaboration with Vertex Pharmaceuticals in connection with its ABCL635 hot-flash drug program. The report did not disclose the collaboration’s financial terms, scope, development…

News · 2026-08-24

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex Pharmaceuticals is progressing with its planned acquisition of Crinetics Pharmaceuticals. The reported transaction value is approximately $10 billion, exceeding the materiality threshold. Crinetics was reported…
• Crinetics Acquisition FinancingImportance 58 · Surprise 42
  Third-party reporting says Vertex is progressing with its approximately $10 billion acquisition of Crinetics Pharmaceuticals. The report references the transaction in connection with Crinetics’ second-quarter 2026…

News · 2026-08-23

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex Pharmaceuticals is progressing with its planned acquisition of Crinetics Pharmaceuticals. The reported transaction value is approximately $10 billion, exceeding the materiality threshold. Crinetics was reported…

News · 2026-08-22

• Guidance / OutlookImportance 75 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to US$13.1 billion–US$13.2 billion. The increase reflects continued cystic-fibrosis treatment demand and growing contributions from CASGEVY and JOURNAVX in sickle-cell…

News · 2026-08-21

• Guidance / OutlookImportance 75 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to US$13.1 billion–US$13.2 billion. The increase reflects continued cystic-fibrosis treatment demand and growing contributions from CASGEVY and JOURNAVX in sickle-cell…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex announced an acquisition of Crinetics Pharmaceuticals valued at approximately $10 billion. The transaction was expected to close in the third quarter of 2026 and is intended to expand Vertex’s pipeline beyond…
• Revenue Performance and MixImportance 54 · Surprise 40
  Vertex reported quarterly revenue of $3.33 billion, up 12.5% year over year and approximately 12.5% above expectations. Cystic fibrosis treatments remained the primary revenue contributor, while CASGEVY and JOURNAVX…
• Market Demand TrendsImportance 54 · Surprise 40
  Vertex reported strong demand for its cystic fibrosis treatments, which remains the primary driver of commercial performance. Demand is also expanding for CASGEVY in sickle cell disease and beta thalassemia, as well as…

News · 2026-08-20

• Competition and Market PositionImportance 31 · Surprise 42
  A rival’s cystic-fibrosis clinical trial failed, reducing a near-term competitive threat to Vertex’s core cystic-fibrosis franchise. The report characterized Vertex as maintaining market leadership in cystic fibrosis…

News · 2026-08-19

• Guidance / OutlookImportance 47 · Surprise 60
  Vertex raised its full-year guidance, according to third-party reporting on its second-quarter performance. The guidance increase was cited alongside strong second-quarter revenue and the company’s cystic-fibrosis…
• Competition and Market PositionImportance 31 · Surprise 42
  A rival’s cystic-fibrosis clinical trial failed, reducing a near-term competitive threat to Vertex’s core cystic-fibrosis franchise. The report characterized Vertex as maintaining market leadership in cystic fibrosis…
• Revenue Performance and MixImportance 29 · Surprise 22
  Vertex reported quarterly revenue of $3.33 billion, exceeding analyst estimates. Revenue increased 12.5% year over year in the latest quarterly earnings. The reported revenue growth exceeded the materiality threshold…

News · 2026-08-18

• Revenue Performance and MixImportance 47 · Surprise 22
  Vertex Pharmaceuticals reported quarterly revenue of $3.33 billion, up 12.5% year over year. Revenue exceeded consensus expectations despite the company missing the consensus EPS estimate by $0.01 per share. The…

News · 2026-08-17

• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  Vertex proposed acquiring Crinetics Pharmaceuticals in an all-cash transaction. Crinetics shareholders would receive $85.00 for each share owned. The transaction is being reviewed by Kahn Swick & Foti, which is…
• Revenue Performance and MixImportance 47 · Surprise 22
  Vertex reported quarterly revenue of $3.33 billion, exceeding analyst estimates. Revenue increased 12.5% year over year during the quarter. The company narrowly missed consensus EPS at $4.73 despite the revenue…
• Licensing / Collaboration DealsImportance 31 · Surprise 42
  Vertex entered a new collaboration with AbCellera, according to third-party reporting dated August 17, 2026. The collaboration is intended to expand AbCellera’s clinical pipeline and diversify revenue beyond its lead…
• Litigation and Legal RiskImportance 31 · Surprise 42
  Kahn Swick & Foti announced an investigation into the adequacy of the price and process of Vertex’s proposed acquisition of Crinetics Pharmaceuticals. Under the proposed transaction, Crinetics shareholders would…

News · 2026-08-16

• Licensing / Collaboration DealsImportance 31 · Surprise 42
  On August 16, 2026, Vertex Pharmaceuticals entered a new collaboration with AbCellera Biologics related to AbCellera’s ABCL635 menopause drug program. AbCellera reported positive Phase 2 results and a US$200 million…
• Revenue Performance and MixImportance 29 · Surprise 22
  Vertex Pharmaceuticals reported revenue growth of 12.5% year over year in its recently reported quarter. Revenue exceeded analyst expectations despite a $0.01-per-share earnings miss. The digest does not provide…

News · 2026-08-15

• Revenue Performance and MixImportance 47 · Surprise 22
  Vertex Pharmaceuticals reported revenue growth of 12.5% year over year. Reported earnings were $4.73 per share, slightly below analyst estimates. The digest did not provide segment revenue, geographic revenue, or…

News · 2026-08-14

• Guidance / OutlookImportance 75 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to $13.1 billion-$13.2 billion. The revised outlook reflects stronger reported performance during 2026. The updated range implies continued annual revenue growth from…
• Guidance and OutlookImportance 75 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion. The updated outlook is above the materiality threshold of 3% of total revenue. Third-party commentary attributes longer-term…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex announced an approximately $10 billion acquisition of Crinetics Pharmaceuticals on July 6, 2026. The transaction is intended to strengthen Vertex’s position in endocrinology drugs. The merger received HSR…
• Revenue Performance and MixImportance 54 · Surprise 40
  Vertex’s cystic fibrosis franchise generated approximately $3.21 billion in Q2 2026 revenue. Franchise revenue increased 10% sequentially and 10.6% year over year. The cystic fibrosis franchise therefore remained the…
• End-Market Demand TrendsImportance 54 · Surprise 40
  Vertex’s cystic fibrosis franchise revenue grew 10.6% year over year in the second quarter, indicating continued demand across its core CF treatment market. Revenue also increased 10% sequentially, suggesting sustained…
• Capital Return ProgramImportance 46 · Surprise 42
  Vertex completed a US$1.42 billion share repurchase program. The amount exceeds the specified US$100 million revenue materiality threshold. The reported buyback followed a 90-day share-price return of 18.19%, although…

News · 2026-08-11

• Revenue Performance and MixImportance 83 · Surprise 60
  Vertex reported Q2 2026 revenue of approximately $3.3 billion, exceeding analyst estimates. Revenue growth was driven by the cystic fibrosis portfolio and newer products including CASGEVY and JOURNAVX. The company…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex agreed to acquire Crinetics Pharmaceuticals for US$85 per share in cash, implying a transaction value of approximately US$10 billion. The deal is expected to close in the third quarter of 2026, subject to…
• Competition and Market PositionImportance 33 · Surprise 42
  Sionna Therapeutics’ SION-719 failed its Phase 2a primary endpoint as an add-on to Vertex’s Trikafta. The candidate showed no significant additive benefit, reducing a potential competitive threat to Vertex’s cystic…

News · 2026-08-10

• Revenue Performance and MixImportance 83 · Surprise 60
  Vertex reported Q2 2026 revenue of approximately $3.3 billion, exceeding analyst estimates. Revenue growth was driven by the cystic fibrosis portfolio and newer products including CASGEVY and JOURNAVX. The company…
• Guidance and OutlookImportance 83 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion after reporting stronger-than-expected second-quarter results. The revised outlook reflects continued demand for its cystic fibrosis…
• Licensing / Collaboration DealsImportance 34 · Surprise 42
  Vertex entered a collaboration with AbCellera for multispecific T-cell engagers. The agreement provides AbCellera with $28 million in upfront consideration. The collaboration is intended to diversify Vertex’s pipeline…
• Product / Drug Pipeline ProgressImportance 33 · Surprise 42
  Vertex reported positive Phase 3 data for its non-opioid pain treatment, supporting continued development of JOURNAVX as a growth product beyond cystic fibrosis. Third-party coverage also identified CASGEVY and…
• Competition and Market PositionImportance 33 · Surprise 42
  Sionna Therapeutics’ SION-719 failed its Phase 2a primary endpoint as an add-on to Vertex’s Trikafta. The candidate showed no significant additive benefit, reducing a potential competitive threat to Vertex’s cystic…

News · 2026-08-09

• Guidance / OutlookImportance 66 · Surprise 60
  Vertex reported strong second-quarter 2026 results, indicating improved quarterly performance. The company upgraded its full-year 2026 revenue guidance, raising its expected revenue outlook. Vertex identified pipeline…
• Licensing / Collaboration DealsImportance 28 · Surprise 42
  Vertex entered a new collaboration with AbCellera Biologics in connection with its 2026 pipeline strategy. The collaboration supports Vertex’s diversification beyond cystic fibrosis into pain, kidney, and type 1…
• Acquisition / Partnership / DivestitureImportance 28 · Surprise 42
  Vertex entered a new collaboration with AbCellera Biologics in 2026. The report provides no disclosed transaction value, jurisdiction-specific obligations, milestone payments, or development timetable. The…
• Product / Drug Pipeline ProgressImportance 23 · Surprise 24
  Vertex’s portfolio remains centered on cystic fibrosis therapies, including Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek. These therapies are described as market leaders in cystic fibrosis treatment,…

News · 2026-08-07

• Revenue Performance and MixImportance 36 · Surprise 40
  Vertex’s second-quarter 2026 revenue increased 12% year over year to $3.33 billion. Cystic fibrosis therapies remained the primary growth driver, while CASGEVY in sickle cell disease and beta thalassemia and JOURNAVX…

News · 2026-08-05

• Revenue Performance and MixImportance 36 · Surprise 40
  Vertex’s second-quarter 2026 revenue increased 12% year over year to $3.33 billion. Cystic fibrosis therapies remained the primary growth driver, while CASGEVY in sickle cell disease and beta thalassemia and JOURNAVX…

10-Q · 2026-08-04

• Geographic Revenue ShiftImportance 54 · Surprise 40
  Second-quarter 2026 U.S. revenue increased 11% year over year to $2,056.4 million, while ex-U.S. revenue increased 14% to $1,277.5 million. First-half U.S. revenue increased 9% to $3,832.3 million, and ex-U.S. revenue…
• Geographic Market CommentaryImportance 54 · Surprise 40
  U.S. revenue increased 11% in the second quarter and 9% in the first half of 2026, reflecting strong patient demand, new ALYFTREK initiations, higher realized CF net prices, and contributions from CASGEVY and JOURNAVX.…
• Capital Return ProgramImportance 49 · Surprise 32
  First-half 2026 financing cash outflows were $965.5 million, compared with $1.0 billion in the prior-year period. The financing outflows primarily reflected common-stock repurchases and shares withheld for employee tax…
• Product Launch and TransitionImportance 47 · Surprise 60
  Vertex is expanding ALYFTREK through regulatory submissions for children aged two to five following positive Phase 3 results. CASGEVY received FDA approval for children aged two and older with SCD or TDT, potentially…
• Regulatory Approval MilestonesImportance 47 · Surprise 60
  The FDA approved CASGEVY for children at least two years old with sickle cell disease or transfusion-dependent beta thalassemia, potentially adding approximately 5,500 eligible patients. Vertex completed submissions in…
• Litigation and Legal RiskImportance 47 · Surprise 60
  On October 10, 2025, Royalty Pharma initiated confidential arbitration concerning the royalty burden payable on ALYFTREK under Vertex’s agreement with the Cystic Fibrosis Foundation. Royalty Pharma alleges that the…
• Income Tax Rate ChangesImportance 44 · Surprise 58
  Vertex’s effective tax rate was 16.6% in the first half of 2026, down from 19.4% in the first half of 2025, a decline of 2.8 percentage points. The lower 2026 rate was primarily attributable to excess tax benefits from…
• Reimbursement and Payer MixImportance 37 · Surprise 42
  Vertex secured ALYFTREK reimbursement in four additional countries during the second quarter of 2026, bringing reimbursement coverage to 25 countries, and signed a letter of intent with the Pan-Canadian Pharmaceutical…
• Supply Chain ConstraintsImportance 29 · Surprise 24
  Vertex relies on a global network of third-party manufacturers and distributors, including some suppliers in China, alongside internal capabilities. The company is establishing supply chains for newly approved products…